Abstract：Objective: To investigate the relationship between immunoglobulin A nephropathy (IgAN) and membranous nephropathy (MN) in renal pathology and serum immunoglobulin and complement values, so as to provide scientific basis for assistant diagnosis of primary glomerular diseases. Methods: 332 patients with IgAN and MN, 85 in IgAN group and 247 in MN group were enrolled in our hospital. The blood biochemical and pathological indexes were measured respectively, and the results were compared. Results: The intensity of complement C3 pathological immune complex in IgAN group was stronger than that in MN group (P<0.01), and the deposition level of IgG pathological immune complex was weaker than that in MN group (P<0.01). The sIgA and sIgG values in IgAN group were higher than those in MN group (P<0.01, P<0.01), and the values of sC3 and sC4 were lower than those in MN group (P<0.01, P<0.01). The levels of BUN and SCR in IgAN group were higher than those in MN group (P<0.01, P<0.05). The levels of sC3 and sC4 in MN group were negatively correlated with the intensity of C3 pathological immune complex (P<0.05, P<0.05); the levels of sC3 in MN group were negatively correlated with the intensity of C3 pathological immune complex (P<0.05); the levels of Scr and sIgA in IgAN group were negatively correlated with the intensity of IgG (P<0.05, P<0.05); the levels of sIgG in MN group were negatively correlated with the intensity of IgG (P<0.05). Conclusion: There are differences in immunoglobulin, complement pathology and serological levels in patients with IgAN and MN, and their manifestations are different in different diseases. Immunoglobulin, complement pathology and serological levels are closely related to IgAN and MN. Therefore, the intensity of pathological grade can be predicted by monitoring serological indicators.
李强, 胡桂才, 孙楠. 原发性肾小球疾病患者免疫球蛋白补体水平与免疫病理比较研究[J]. 河北医学, 2019, 25(12): 2098-2103.
LI Qiang, HU Guicai, SUN Nan. Comparative Study on Immunoglobulin, Complement Levels and Immunopathology in Patients with Primary Glomerular Disease. HeBei Med, 2019, 25(12): 2098-2103.
[1] Lai KN, Tang SCW, SchenaFP,et al. IgA nephropathy[J]. Nat Rev Dis Primers,2016,2:16002. [2] Couser W G.Primary membranous nephropathy[J].Clin Am Soc Nephrol,2017,12(6):983~997. [3] Thaminda Liyanage, Toshiharu Ninomiya, Vivekanand Jha,etc.Worldwide access to treatment for end-stage kidney disease: a systematic review[J]. Lancet,2015,385:1975~1982. [4] Sinico R A, Mezzina N , Trezzi B , et al. Immunology of membranous nephropathy: from animal models to humans[J]. Clinical & Experimental Immunology, 2016, 183(2):157~165. [5] 段梦夕,刘博智,曹华军,等.血清IgA/C3在IgA肾病辅助诊断及病情监测中的应用[J].实用医学杂志,2018,34(8):1330~1334. [6] 施映枫,徐柳青,庄守纲,等.IgA肾病患者病理与临床指标的相关性分析[J].上海交通大学学报(医学版),2017,37(10):1362~1367. [7] ThomasRauen,JurgenFloege.Inflammation in IgA nephropathy[J]. Pediatric Nephrology,2017,32(12):2215~2224. [8] Maixnerova D, et al.Markers for the progression of IgA nephropathy[J].Nephrol,2016,29(4):535~541. [9] 王文涛,黄婷,何堤,等.成人原发性IgA肾病与血免疫球蛋白及补体的相关关系[J].山西医科大学学报,2018,49(8):963~967.
2019, Vol. 25 
冀公网安备13080202000677号